MedTrace Logo

Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome

NCT03847571 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-02-20

No results posted yet for this study

Summary

In this prospective controlled cross over clinical trial, the investigators aim to evaluate the efficacy and safety of acetazolamide for the management of metabolic alkalosis in children with Bartter syndrome. Urine and blood electrolytes will be measured before and after acetazolamide treatment. The primary end point is a change in polyuria, hypokalemia, and metabolic alkalosis.

Conditions

  • Bartter Syndrome

Interventions

DRUG

Acetazolamide

Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Farahnak Assadi, MD · Rush University Medical Center

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2019-10-30
Completion
2019-12-30
FDA Drug
Yes

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03847571 on ClinicalTrials.gov